Success Story: Advancing Targeted Cancer Therapies: A Structural Biologist’s NIW Approval
Client’s Testimonial:
"Thank you again for the successful application.”
On March 27th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the Field of Structural Biology (Approval Notice).
General Field: Structural Biology
Position at the Time of Case Filing: Postdoctoral Researcher
Country of Origin: Canada
Approval Notice Date: March 27th, 2026
Processing Time: 14 months, 10 days (Premium Processing Upgrade Requested)
Case Summary:
The client works in the highly specialized field of structural biology. Their proposed endeavor is to continue analyzing the structures and mechanisms of proteins altered in cancer in order to guide the design of novel cancer therapies and treatments. The petition framed this work as an area of clear, substantial merit and national importance because it addresses a central challenge in oncology: understanding how cancer-related proteins function so that more precise and effective therapies can be developed. The petition also noted that the client is currently employed as a postdoctoral researcher, where they continue this line of research.
The national importance of the client’s work was presented through both public health and economic impact. The petition explained that cancer cases are expected to continue rising, while cancer care already imposes a heavy financial burden in the United States. Against that backdrop, the client’s research was positioned not as abstract laboratory work, but as a scientifically grounded effort to support better treatment design and improve outcomes for patients facing serious disease.
To show that the client was well-positioned to advance this endeavor, we highlighted a focused but high-value publication record of 4 peer-reviewed journal articles, including 1 first-authored paper. Rather than treating the number alone as sufficient, the petition explained that these papers appeared in highly regarded journals, which supported the argument that the client’s methods and findings had already passed demanding editorial and peer scrutiny.
We then emphasized the strongest objective evidence of significance: 611 citations to the client’s published work. The petition did not rely on the raw number by itself. Instead, it showed that one article ranked among the top 1% most cited papers in its field and publication year. That matters because percentile-based evidence helps an adjudicator see that the client’s influence is not merely respectable, but exceptional relative to field norms. The petition further showed that other researchers had directly relied on the client’s findings in later studies, reinforcing that the work had already shaped ongoing research in structural biology and cancer treatment development.
We were delighted to secure this I-140 NIW approval for a researcher whose structural biology work is already helping illuminate how altered proteins can be studied and targeted, paving the way for future advances in cancer therapy.